Triglide

Triglide is a brand name of fenofibrate, approved by the FDA in the following formulation(s):

TRIGLIDE (fenofibrate - tablet; oral)

• 
  Manufacturer: SKYEPHARMA AG
  
  Approval date: May 7, 2005
  
  Strength(s): 50MG
  

Has a generic version of Triglide been approved?

No. There is currently no therapeutically equivalent version of Triglide available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Triglide. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Spray drying process and compositions of fenofibrate
  Patent 6,696,084
  Issued: February 24, 2004
  Inventor(s): Gary W.; Pace & Awadesh K.; Mishra & Robert A.; Snow & Indu; Parikh & Pol-Henri W.; Guivarc'h
  Assignee(s): RTP Pharma Inc.
  The present invention relates to a novel spray drying process for the preparation of pharmaceutical compositions containing small particles of phospholipid-stabilized fenofibrate. This invention also relates to spray dried powdered compositions prepared according to this process, and to dosage forms of fenofibrate (capsules, tablets, powders, granules, and dispersions) prepared from these powdered compositions. The powdered compositions and dosage forms are useful in the treatment of dyslipidemia and dyslipoproteinemia and have the advantage that they provide reduced in vivo variability in the bioavailability of fenofibrate active species among fed and fasted patients when administered orally.
  
  Patent expiration dates:
  
  
  • September 11, 2021
    
    ✓ 
    Patent use: A METHOD OF TREATING DYSLIPIDEMIA AND DYSLIPOPROTEINEMIA USING A DOSAGE FORM THAT CAN PROVIDE AN EFFECTIVE AMOUNT OF FENOFIBRATE TO A PATIENT IN A FASTED STATE WHICH IS AT LEAST 90% OF THE AUC AMOUNT PROVIDED BY THE DOSAGE FORM
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  

See also...

• Triglide Consumer Information (Cerner Multum)
• Triglide Advanced Consumer Information (Micromedex)
• Fenofibrate Consumer Information (Drugs.com)
• CIP - Fenofibrate Consumer Information (Wolters Kluwer)
• Fenofibrate Consumer Information (Wolters Kluwer)
• Fenofibrate Consumer Information (Cerner Multum)
• Fenofibrate Advanced Consumer Information (Micromedex)
• Fenofibrate AHFS DI Monographs (ASHP)